share_log

Hypera S.A. (OTCMKTS:HYPMY) Short Interest Update

Hypera S.A. (OTCMKTS:HYPMY) Short Interest Update

Hypera S.A.(場外交易代碼:HYPMY)空頭股數更新
kopsource ·  2022/07/15 21:51

Hypera S.A. (OTCMKTS:HYPMY – Get Rating) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totalling 800 shares, a decline of 75.0% from the June 15th total of 3,200 shares. Based on an average daily trading volume, of 14,000 shares, the short-interest ratio is currently 0.1 days.

Hypera S.A.(場外交易代碼:HYPMY-GET Rating)是6月份空頭股數股價大幅下降的接收方。截至6月30日,空頭股數共有800股,較6月15日的3200股下降了75.0%。以日均成交量1.4萬股計算,目前短息比為0.1天。

Hypera Stock Performance

Hypera股票表現

HYPMY stock traded up $0.18 during trading on Friday, reaching $7.36. 2,840 shares of the company were exchanged, compared to its average volume of 16,894. Hypera has a 52-week low of $4.63 and a 52-week high of $8.89. The company has a market cap of $4.66 billion, a P/E ratio of 17.52 and a beta of 0.77. The stock's 50 day moving average price is $7.59 and its 200 day moving average price is $6.96.

在週五的交易中,HYPMY的股票上漲了0.18美元,達到7.36美元。該公司成交量為2,840股,而其平均成交量為16,894股。Hypera的52周低點為4.63美元,52周高點為8.89美元。該公司市值為46.6億美元,市盈率為17.52倍,貝塔係數為0.77。該股的50日移動均線價格為7.59美元,200日移動均線價格為6.96美元。

Get
到達
Hypera
金絲桃組
alerts:
警報:

About Hypera

關於Hypera

(Get Rating)

(獲取評級)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.
Hypera SA在巴西作為一家制藥公司運營。它提供的處方藥有Adacne、Addera、Apri、AmpliumG、請、賽萊他明、Celstone、Celstone Soluspana、Cizax、DECPRAX、衍生CMicro、Micro Drift、Dermol Fusid、Digedrat、雙丙胺、雙丙沙星、雙丙鬆、雙丙鬆、Emprol XR、Flow、Garasone、Halobx、Lipanon、Moon、Lydian、Macrodantin、MaxSulid、MilGamma、Mioflex-A、Nesina、Novotram、oximax、peridid、Perida混懸劑、Predsim、Pressaliv、Quadriderm、Rizi、Rizi、Softalm、acrotz、tinodin、umma和velunid品牌。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Hypera (HYPMY)
  • MarketBeat: Week in Review 7/11 – 7/15
  • Is Coupang's Stock On The Verge Of A Turnaround?
  • Should You Have These Two Banks In Your Portfolio?
  • Verint Systems Stock is a Customer Engagement Play
  • Why Shopify Stock Split...And is as Shoppable as Ever
  • 免費獲取StockNews.com關於Hypera的研究報告(HYPMY)
  • MarketBeat:回顧一週7/11-7/15
  • Coupang的股票即將翻身嗎?
  • 你的投資組合中應該有這兩家銀行嗎?
  • Verint Systems Stock是一場客户互動活動
  • 為什麼Shopify股票拆分...並一如既往地適合購物

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.

接受Hypera Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Hypera和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論